Orient (605116.SH): Enzalutamide tablets and didroprogesterone tablets to be selected for the 12th batch of centralized volume procurement

Zhitongcaijing · 2d ago

Zhitong Finance App News, Orient (605116.SH) issued an announcement. On July 31, 2026, the company participated in the 12th batch of national centralized drug procurement tenders organized by the Joint Pharmaceutical Procurement Office of the State Organization. According to the “12th Batch Centralized Drug Procurement Results Table (GY-YD2026-1)” issued by the Joint Procurement Office, the company plans to select enzalumide tablets and didrogesterone tablets from the 12th batch for centralized volume procurement.

This centralized drug procurement is the 12th batch of centralized procurement of national drugs organized by the state. In terms of implementation, medical institutions are required to prioritize the use of selected varieties from centralized procurement and ensure that the agreed procurement volume is completed. If the company subsequently signs a procurement contract and implements it, it will help the above products to quickly open up the domestic market, increase market share, enhance the company's brand influence, and have a positive impact on the company's future operations.